(Q35282945)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

David C Turner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Todd D Tillmanns

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

K Elaine Harstead

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Stacy L Throm

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Clinton F Stewart

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

3823-3829

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

20 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Oral topotecan: bioavailablity and effect of food co-administration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Clinical pharmacokinetics of topotecan

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4386652

Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24023315

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24023315

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24023315

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

24023315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24023315%20AND%20SRC:MED&resulttype=core&format=json